Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.31 |
| ▸ | MTOR | P42345 | 8/20 | 0.31 |
| ▸ | RPTOR | Q8N122 | 7/20 | 0.31 |
| ▸ | MLST8 | Q9BVC4 | 7/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.31 |
| ▸ | RICTOR | Q6R327 | 4/20 | 0.31 |
| ▸ | MAPKAP1 | Q9BPZ7 | 4/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.31 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19362359 | 0.89 | PDE10A (0.36) | PDE10AKDM4EHPGDALDH1A1 | |
| SCHEMBL19362352 | 0.77 | HIF1A (0.36) | — | |
| SCHEMBL19362269 | 0.74 | PIK3CA (0.30) | PIK3CAMTOR | |
| SCHEMBL19362421 | 0.74 | HTR2A (0.33) | — | |
| SCHEMBL19360176 | 0.73 | CNR2 (0.33) | PIK3CAMTORRPTORMLST8PIK3R1 | |
| SCHEMBL19362266 | 0.72 | — | — | |
| SCHEMBL19362229 | 0.69 | — | — | |
| SCHEMBL19362373 | 0.66 | PDE10A (0.34) | PDE10AKDM4EHPGDALDH1A1 | |
| SCHEMBL19362417 | 0.66 | PDE10A (0.34) | PDE10AKDM4EHPGDALDH1A1 | |
| SCHEMBL19362348 | 0.66 | MCHR1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267679-A1 | TRICYCLIC FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF p97 COMPLEX | CLEAVE BIOSCIENCES INC (US) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267679-A1 | TRICYCLIC FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF p97 COMPLEX | PSMG3, PSME1, PSMB3 | PDE10A 4409/4885KDM4E 3241/4885HPGD 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.